In early trading on Wednesday, shares of Gilead Sciences topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.0%. Year to date, Gilead Sciences registers a ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

Biogen Inc. (BIIB) is expected to deliver a year-over ... estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top ...

SAGE is currently trading at $24.93, up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at $147.98 up 1.21 percent or $1.78 on the Nasdaq. The views and opinions expressed herein ...

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi. Post the FDA approval ...

Analysts on Wall Street project that Biogen Inc. (BIIB) will announce quarterly earnings of $3.45 per share in its forthcoming report, representing an increase of 17% year over year. Revenues are ...

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...